{"id":609,"date":"2013-02-06T22:56:45","date_gmt":"2013-02-06T22:56:45","guid":{"rendered":"http:\/\/microbiologymatters.com\/?p=609"},"modified":"2013-02-07T01:17:57","modified_gmt":"2013-02-07T01:17:57","slug":"anti-microbial-stewardship-in-the-hospital-settingthe-vicious-circles-of-resistance","status":"publish","type":"post","link":"https:\/\/microbiologymatters.com\/?p=609","title":{"rendered":"Anti-microbial Stewardship in the Hospital Setting: &#8220;The Vicious Circles of Resistance&#8221;"},"content":{"rendered":"<p>Here are\u00a0a few\u00a0vicious circles that make the job of anti-microbial stewardship even more difficult than it already is:<\/p>\n<p><span style=\"color: #ff0000;\">1) Increasing\u00a0rates of\u00a0Multi-Drug Resistant Organisms (MDROs) increases the use of broad spectrum anti-microbials, which in turn increases further the MDRO rate. <span style=\"color: #0000ff;\">This is probably the main vicious circle at play. To break it requires a lot of work put into predicting which patient cohorts absoulutely need broad spectrum antimicrobials, and which cohort can &#8220;get away with&#8221; a narrower spectrum anti-microbial in the first instance.<\/span><\/span><\/p>\n<p><span style=\"color: #ff0000;\">2) Increasing availability of broad spectrum anti-microbials on the hospital formulary increases use of broad spectrum antimicrobials, which increases the resistance rates, which in turn\u00a0encourages more broad spectrum antimicrobials being placed on the formulary.<span style=\"color: #0000ff;\"> The premise behind this vicious circle is that if something is available, it is used. Institutions need to think very carefully what broad spectrum anti-microbials it has on their formulary. &#8220;just in case&#8221; or &#8220;personal preference&#8221; for me are poor arguments in the bigger scheme of things.<\/span><\/span><\/p>\n<p><span style=\"color: #ff0000;\">3) Increasing numbers of patients with MDROs on a ward increases chances of patients on the ward without MDROs being colonised with an MDRO, thus increasing tranmission risk further. <span style=\"color: #0000ff;\">The <strong>cascade effect<\/strong>. If I was lying in ICU with 7 other patients, and 5 of them have MDRO colonisation, then regardless of how good Infection Control is, I don&#8217;t fancy my chances of staying MDRO free.<\/span><\/span><\/p>\n<p><span style=\"color: #ff0000;\">4) Increasing MDRO rates leads to less chance of properly isolating patients, thus increases chances of MDRO transmission, which increases the MDRO rate. <span style=\"color: #0000ff;\">Not dissimilar to 3). We know some institutions have\u00a0&#8220;run\u00a0out&#8221; of isolation facilities, and thus have to prioritise Isolation Facilities to the highly Multi Resistant Drug Organisms (hMDROs)<\/span><\/span><\/p>\n<p><span style=\"color: #ff0000;\"><span style=\"color: #0000ff;\">\u00a0<\/span><\/span><span style=\"color: #ff0000;\">5) Higher MDRO rates, leads to antibiotic policies which include more broad spectrum antimicrobials which in turn further increases MDRO rates. <span style=\"color: #0000ff;\">If you have a hospital with very low MDRO rates, then it is much easier to\u00a0omit antimicrobials like tigecycline, meropenem, daptomycin, linezolid etc etc,\u00a0from your &#8220;admission antimicrobial policies&#8221;. <\/span><\/span><\/p>\n<p>(<em>If I was an artist I would illustrate these vicious circles <strong>as circles. <\/strong>Alas it was not to be..!)<\/em><\/p>\n<p>There\u00a0are almost certainly more vicious circles at play but I think these are the main ones.<\/p>\n<p>I think these vicious circles go some way to explaining the vast differences in MDRO rates that we see between different institutions.<\/p>\n<p>And the solution? I don&#8217;t think there is any miracle solution here. I certainly do not like defeatist attitudes as I have encountered in some hospitals with high MDRO rates. I.e. &#8220;No point in shutting the stable door after the horse has bolted.&#8221; I think the UK&#8217;s recent impact on MRSA rates shows that these vicious circles can be broken. However it requires a combination of strong leadership, co-operation between different stakeholders, and political will.<\/p>\n<p>Food for thought&#8230;..<\/p>\n<p><em>Michael<\/em><\/p>\n<p>See also <a title=\"\u201cAntimicrobial Stewardship in the Hospital Setting: The Dilemma\u2026.\u201d\" href=\"http:\/\/microbiologymatters.com\/?p=512\">&#8220;Anti-microbial stewardship in the Hospital Setting: The dilemma.&#8221;<\/a><\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Here are\u00a0a few\u00a0vicious circles that make the job of anti-microbial stewardship even more difficult than it already is: 1) Increasing\u00a0rates of\u00a0Multi-Drug Resistant Organisms (MDROs) increases the use of broad spectrum anti-microbials, which in turn increases further the MDRO rate. This is probably the main vicious circle at play. To break it requires a lot of &hellip; <a href=\"https:\/\/microbiologymatters.com\/?p=609\" class=\"more-link\">Continue reading <span class=\"screen-reader-text\">Anti-microbial Stewardship in the Hospital Setting: &#8220;The Vicious Circles of Resistance&#8221;<\/span> <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","enabled":false}}},"categories":[14],"tags":[36,33,34],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/p37jIp-9P","jetpack-related-posts":[{"id":512,"url":"https:\/\/microbiologymatters.com\/?p=512","url_meta":{"origin":609,"position":0},"title":"&#8220;Antimicrobial Stewardship in the Hospital Setting: The Dilemma&#8230;.&#8221;","author":"michael","date":"January 31, 2013","format":false,"excerpt":"The Dilemma (or is it dilemna!) The individual patient v the population: Potentially every patient that walks in the door\u00a0of the hospital\u00a0with clinical\u00a0sepsis could be given the\u00a0broadest spectrum antimicrobial available on the formulary. This might give the individual the best chance of survival from their sepsis but such management will\u2026","rel":"","context":"In &quot;Antimicrobial Resistance&quot;","block_context":{"text":"Antimicrobial Resistance","link":"https:\/\/microbiologymatters.com\/?cat=14"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":731,"url":"https:\/\/microbiologymatters.com\/?p=731","url_meta":{"origin":609,"position":1},"title":"&#8220;Chasing the Dragon&#8221;","author":"michael","date":"February 14, 2013","format":false,"excerpt":"There has been a lot of coverage in recent years on the topic of \"Bad Bugs, No Drugs\", along with some concerted pressure on governments to fund greater research into the development of\u00a0new and original antimicrobials. The focus on this as an absolute priority sits a little uneasily with me....\u2026","rel":"","context":"In &quot;Antimicrobial Resistance&quot;","block_context":{"text":"Antimicrobial Resistance","link":"https:\/\/microbiologymatters.com\/?cat=14"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":2643,"url":"https:\/\/microbiologymatters.com\/?p=2643","url_meta":{"origin":609,"position":2},"title":"&#8220;Keeping a Low Profile&#8221;","author":"michael","date":"January 5, 2016","format":false,"excerpt":"What do tigecycline, daptomycin, ceftaroline, have in common? They are all relatively new broad spectrum antibiotics, to which various\u00a0MDROs are often susceptible. They are also manufactured and marketed by pharmaceutical companies in whose basic\u00a0interest it is that we use as much of these antibiotics as possible. However to maintain the\u2026","rel":"","context":"In &quot;Antimicrobial Resistance&quot;","block_context":{"text":"Antimicrobial Resistance","link":"https:\/\/microbiologymatters.com\/?cat=14"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":2745,"url":"https:\/\/microbiologymatters.com\/?p=2745","url_meta":{"origin":609,"position":3},"title":"&#8220;Pressure Control&#8221;","author":"michael","date":"February 5, 2016","format":false,"excerpt":"Controlling the volume of Multi-Drug Resistant Organisms\u00a0(MDROs)\u00a0within\u00a0an institution is just as much about controlling the selection pressure as it is about controlling the transmission. (Don't tell the Infection Control nurses that, but it is absolutely true!) In my opinion the selection pressure control is actually the more important of the\u2026","rel":"","context":"In &quot;Antimicrobial Resistance&quot;","block_context":{"text":"Antimicrobial Resistance","link":"https:\/\/microbiologymatters.com\/?cat=14"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":288,"url":"https:\/\/microbiologymatters.com\/?p=288","url_meta":{"origin":609,"position":4},"title":"&#8220;Focused Anti-microbial Reporting.&#8221;","author":"michael","date":"January 10, 2013","format":false,"excerpt":"\"Note this post is really only useful for people who are working\/preparing to work\/might work in a clinical microbiology laboratory.\" The antimicrobials that are \u201creleased\u201d\u00a0 to clinicians vary enormously from lab to lab. When I say released I mean the antibiotic susceptibilities which are available for the clinicians to view.\u2026","rel":"","context":"In &quot;The Science of Microbiology&quot;","block_context":{"text":"The Science of Microbiology","link":"https:\/\/microbiologymatters.com\/?cat=4"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":3038,"url":"https:\/\/microbiologymatters.com\/?p=3038","url_meta":{"origin":609,"position":5},"title":"&#8220;The Transition&#8221;","author":"michael","date":"August 11, 2016","format":false,"excerpt":"At present, routine anti-microbial susceptibility testing is still dominated by phenotype, with genotypic testing occasionally getting a look in for MDROs. I doubt\u00a0this is likely to be the case forever... As our knowledge of genotypic resistance determinants increases, and the cost continues to decrease, I see a time when first\u2026","rel":"","context":"In &quot;Antimicrobial Resistance&quot;","block_context":{"text":"Antimicrobial Resistance","link":"https:\/\/microbiologymatters.com\/?cat=14"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]}],"_links":{"self":[{"href":"https:\/\/microbiologymatters.com\/index.php?rest_route=\/wp\/v2\/posts\/609"}],"collection":[{"href":"https:\/\/microbiologymatters.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/microbiologymatters.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/microbiologymatters.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/microbiologymatters.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=609"}],"version-history":[{"count":6,"href":"https:\/\/microbiologymatters.com\/index.php?rest_route=\/wp\/v2\/posts\/609\/revisions"}],"predecessor-version":[{"id":618,"href":"https:\/\/microbiologymatters.com\/index.php?rest_route=\/wp\/v2\/posts\/609\/revisions\/618"}],"wp:attachment":[{"href":"https:\/\/microbiologymatters.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=609"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/microbiologymatters.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=609"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/microbiologymatters.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=609"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}